Jason D’Orlando, a North America vice president at Turner & Townsend, wrote the research article dealing with pharmaceutical construction delays and said that the “need for speed” causes some pharma companies to hurry through planning and to rely too much on historical project data. Companies end up requesting the necessary funding without validating their conceptual estimates and without a thorough schedule and costs analysis. Basing their projections on outdated or incorrect numbers also leads to higher engineering costs.
